Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.
The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
http://legaljusticeadvocates.com
Aiding those in need, this explainer video for Legal Justice Advocates a team of lawyers with more than 40 years of combined experience to enforce clients' rights when it comes to disability discrimination and other forms of unequal treatment in the workplace and elsewhere. Legal Justice Advocates also handles consumer protection claims, bankruptcy and collections matters. The advocacy law firm can be reached at (202)803-4708 or go to their website and learn more at: http://legaljusticeadvocates.com
Extremely painful and destructive, gout is the most common form of inflammatory arthritis with elevated serum uric acid (sUA) a root cause of the disease. Even with the growing incidence of gout, recent research from the Gout & Uric Acid Education Society (GUAES) found that just 16 percent of Americans overall know the target sUA number for gout (6 mg/dL or below) – and just 38 percent of people with gout had their sUA levels checked within the past six months, the timeframe recommended by the American College of Rheumatology. Additionally, the majority of gout sufferers don’t understand the importance of taking daily uric acid-lowering medications, with four in 10 incorrectly believing that they can stop taking medications when they aren’t experiencing flares.
Seeking to increase recognition of the severity of gout and need for routine sUA testing and management, GUAES hosted a professional roundtable discussion on October 3, 2015. The roundtable brought together several experts – rheumatologists, a family care physician, and representatives from the American Association of Diabetes Educators, the National Kidney Foundation and CreakyJoints – to explore how to more effectively educate about gout and improve access to public education and treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7715851-guaes-gout-roundtable-discussion/
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced the winners of its 2016 Health Hero Awards (http://www.webmd.com/healthheroes/what-is-hero), recognizing individuals who are changing the healthcare landscape by meeting a health challenge and giving back to others. This year’s winners are Seth Rogen and Lauren Miller Rogen, Ed Damiano, PhD, Betty Ferrell, RN, PhD and Trisha Prabhu.
On November 3, 2016, an accomplished and inspiring lineup of presenters and performers will gather to honor the winners at the 3rd Annual WebMD Health Hero Awards gala, hosted by Good Morning America co-anchor Robin Roberts. This year’s presenters include David Krumholtz, Adam Savage, and Sarah Wynter, with musical performances by A Great Big World and Naturally 7.
To watch the red carpet arrivals as they happen live from the TimesCenter in New York City, follow WebMD on www.facebook.com/webmd beginning at 6:30 PM ET on November 3, and be sure to follow @WebMD on Instagram, Snapchat and Twitter for updates throughout the night with #HealthHeroes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579756-webmd-2016-health-hero-awards/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
For North America
Dr. Danielle Marcoux from Canada
Camp Liberté – Summer camp for children with skin disorders
This one-week summer camp run by volunteer dermatologists and nurses enrolled children aged 7 to 12 with moderate-to-severe skin disorders, as well as their families, to bring them together for support, social interaction and to increase their confidence. All the activities aim to increase patients’ confidence and self-esteem, improve social skills, reduce stigma about their condition and improve adherence to treatment.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
L’Oréal announced the winners of its International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” at the 23rd World Congress of Dermatology taking place in Vancouver, Canada.
Dr. Ksenia Sorokina from Russia
A healthy child means a healthy family- Targeting prevention of dermatitis and adherence to treatment
This project consists of providing training workshops for parents and children with chronic skin diseases and developing the first ever website to allow patients living in remote areas of the Russian Federation to access a consultation with a dermatologist, as well as attend online training seminars for people presenting chronic dermatitis and to increase adherence to therapy for patients as well as their parents, within four Russian territories.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7554651-loreal-announces-2015-awardees/
WebMD Health Corp. (NASDAQ:WBMD), the leading source of health information, today announced the premiere of WebMD’s Future of Health with Robin Roberts, developed in collaboration with Good Morning America co-anchor Robin Roberts and her independent production company, Rock’n Robin Productions. Each Future of Health episode presents stories about cutting-edge medical breakthroughs, inspiring individuals working to improve people’s lives, and the people that are benefiting from their efforts. The five-part digital video series and related programming, which include feature stories, slideshows, quizzes and a host of video extras, are available at http://webmd.com/futureofhealth.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7282551-webmd-future-of-health/
Based on an original story by Roberto Stopello and written by Indira Páez, the new season of the Super Series™ unfolds within the painful context of the undocumented immigrants who cross the border from Mexico to the United States in search of the American Dream. “Señora Acero, La Coyote” continues the story of Vicenta Acero (Carolina Miranda), a strong woman who has carved a path for herself in a male-dominated world and fights for better treatment of the many immigrants who struggle to cross one of the world’s longest borders. In the new season, La Coyote faces enemies on both sides of the law who are out for revenge and to destroy the Acero Quintanilla dynasty.
To view the multimedia release go to:
https://www.multivu.com/players/English/8202051-telemundo-senora-acero-la-coyote/
